The European LeukemiaNet has periodically issued guidelines for the diagnosis and management of acute myeloid leukemia (AML) in adults. These consensus recommendations, most recently updated in 2022, incorporate recent advances in genomic testing, disease detection methods, target identification, and response assessment. Whilst similarities exist between AML in children and adults, pediatric AML is frequently characterized by unique cytogenetic and molecular features, which require distinct genetic and immunophenotypic diagnostics, therapeutic approaches, response assessment criteria, and supportive care strategies. To address these specific needs, an international panel of pediatric hematologist-oncologists, biologists, geneticists, and laboratory medicine scientists convened to develop recommendations for the diagnosis and management of AML in children, adolescents, and young adults (hereafter termed pediatric AML) that are discussed in this special report.
Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert Panel Free
C. Michel Zwaan, Sarah K Tasian, Richard Aplenc, Lisa Eidenschink Brodersen, Barbara Buldini, Barbara De Moerloose, Michael N Dworzak, Linda Fogelstrand, Brenda ES Gibson, Bianca F Goemans, Henrik Hasle, Betsy A Hirsch, Gertjan JL Kaspers, Jan-Henning Klusmann, Matthew A Kutny, Thomas Lehrnbecher, Franco Locatelli, Shoeil Meshinchi, Arnaud Petit, Martina Pigazzi, Anne Tierens, E Anders Kolb, Dirk Reinhardt, Daisuke Tomizawa, Todd M Cooper; Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert Panel. Blood 2025; blood.2024027904. doi: https://doi.org/10.1182/blood.2024027904
Download citation file:
Advertisement intended for health care professionals
Cited By
Advertisement intended for health care professionals
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal